Charles Schwab Investment Management Inc Eye Point Pharmaceuticals, Inc. Transaction History
Charles Schwab Investment Management Inc
- $527 Billion
- Q4 2024
A detailed history of Charles Schwab Investment Management Inc transactions in Eye Point Pharmaceuticals, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 191,165 shares of EYPT stock, worth $1.24 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
191,165
Previous 142,763
33.9%
Holding current value
$1.24 Million
Previous $1.14 Million
24.91%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding EYPT
# of Institutions
151Shares Held
65.9MCall Options Held
143KPut Options Held
173K-
Cormorant Asset Management, LP Boston, MA8.33MShares$54.1 Million4.9% of portfolio
-
Suvretta Capital Management, LLC New York, NY6.78MShares$44.1 Million2.1% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA5.75MShares$37.4 Million0.08% of portfolio
-
Franklin Resources Inc San Mateo, CA4.14MShares$26.9 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.8MShares$24.7 Million0.0% of portfolio
About EyePoint Pharmaceuticals, Inc.
- Ticker EYPT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 34,072,200
- Market Cap $221M
- Description
- EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intrav...